Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
121.90
-1.91 (-1.54%)
At close: Jul 3, 2025, 1:00 PM
121.84
-0.06 (-0.05%)
After-hours: Jul 3, 2025, 5:00 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.62B in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$53.22B
Revenue Growth
+11.50%
P/S Ratio
4.55
Revenue / Employee
$701,369
Employees
75,883
Market Cap
242.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
NVS News
- 2 days ago - Novartis drug Cosentyx fails late-stage trial for artery disease - Reuters
- 2 days ago - Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA) - PRNewsWire
- 9 days ago - ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease - GlobeNewsWire
- 10 days ago - Novartis completes acquisition of Regulus Therapeutics - GlobeNewsWire
- 10 days ago - Novartis: A SWAN Worth Owning - Seeking Alpha
- 10 days ago - Novartis announces expiration of Regulus Therapeutics tender offer - GlobeNewsWire
- 23 days ago - Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder - Benzinga
- 23 days ago - Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH - GlobeNewsWire